# Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients

Study · id `cardio:ct-nct05360537` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05360537](<https://clinicaltrials.gov/study/NCT05360537>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05360537

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT05360537. Randomized; double masking; primary purpose treatment. Start 2021-04-01 (actual); primary completion 2021-12-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT05360537, source copy `cardio:ctgov-nct05360537-2023-12-15`, retrieved 2026-10-26)
- Started: 2021-04-01 (actual) (ClinicalTrials.gov record NCT05360537, source copy `cardio:ctgov-nct05360537-2023-12-15`, retrieved 2026-10-26)
- Primary completion: 2021-12-01 (actual) (ClinicalTrials.gov record NCT05360537, source copy `cardio:ctgov-nct05360537-2023-12-15`, retrieved 2026-10-26)
- Completion: 2022-04-20 (actual) (ClinicalTrials.gov record NCT05360537, source copy `cardio:ctgov-nct05360537-2023-12-15`, retrieved 2026-10-26)
- Countries: Italy (ClinicalTrials.gov record NCT05360537, source copy `cardio:ctgov-nct05360537-2023-12-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05360537-2023-12-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Insulin Degludec / Liraglutide Injectable Product
- Intervention (Drug): Insulin Glargine
- Lead sponsor: University of Palermo
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: University of Palermo (`cardio:org-university-of-palermo`)

## Provenance

Content hash: ffac486444c2f9f60f9e52613461fc10aaf93b5d344d363abf073da29a74d3df
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
